G1 Therapeutics Provides Third Quarter 2023 Financial Results and Operational Highlights streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Shay Elkins, a patient with metastatic triple-negative breast cancer, discussed her experience with second-line treatment. Dr. Noor provided insights into the positive outcomes from the ASCENT study.
Dr. Noor Abuhadra and patient Shay Elkins discuss overcoming barriers to cancer treatment access and reimbursement. Shay shares her relatively smooth experience with insurance coverage, while Dr. Abuhadra emphasizes that healthcare teams will fight for patient coverage, especially when treatments are backed by research and FDA approval. Dr. Abuhadra also mentions having a financial clearance department to handle denials and secure approvals, as well as training staff to fill out prior authorization forms. Shay underlines the importance of self-advocacy and leveraging online communities for both emotional support and practical advice.
The B cell immunotherapy HER-Vaxx and CF33 oncolytic virotherapy CHECKVacc of Imugene Ltd (ASX:IMU, OTC:IUGNF) (Imugene Ltd (ASX:IMU, OTC:IUGNF), Imugene.